Short description
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Description
Otonomy is an expert in the otology field in order to build the premier company dedicated to the treatment of otic disorders via localized drug delivery. This approach has already been widely adopted for the delivery of short-acting antibiotics to treat otitis media through a tympanostomy tube. In addition, otolaryngologists have demonstrated that the injection of steroids into the middle ear cavity can provide a therapeutic effect for patients with acute inner ear disorders such as Ménière’s disease and sudden sensorineural hearing loss. Expansion of this effort holds great promise for the treatment of chronic hearing loss, severe vertigo, and even tinnitus.
The key to Otonomy's leading position in this nascent field is the development of a proprietary formulation platform that provides sustained drug exposure from a single administration. Broad application of this technology has already been established across a number of therapeutic classes, and from these, three product candidates have been advanced into development.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
San Diego, California, United States, North America
Founded on
January 1, 2008
Closed on
March 27, 2023
Exited on
August 14, 2014
Went public on
August 14, 2014
Stock symbol
OTIC
Non-profit?
No
Acquired?
No
Employees count
51-100
Revenue range
$34056 - 789030
Sign in for full access
Investors
Noaccess, Noway Youcantaccess, Noaccessforu, Blurry Noaccess, Absolutely Noaccess, Cannot Access, Noaccess, Uh Ohhhh, Absolutely Noaccess, Blurry Noaccess, Noaccessforu, Noaccess
Sign in for full access
Founders
Allen F. Ryan, Jay Lichter, Jeffrey Harris